» Authors » Jeffery C Talbert

Jeffery C Talbert

Explore the profile of Jeffery C Talbert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 47
Citations 414
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sehgal S, Pua E, Rojevsky S, Becich M, Fehrmann J, Knosp B, et al.
J Clin Transl Sci . 2025 Mar; 9(1):e28. PMID: 40052053
Introduction: Managing clinical trials is a complex process requiring careful integration of human, technology, compliance, and operations for success. We collaborated with experts to develop a multi-axial Clinical Trials Management...
2.
Jayawardhana J, Hou J, Freeman P, Talbert J
JAMA Psychiatry . 2024 Dec; 82(3):228-236. PMID: 39714863
Importance: Whether state implementation of medical and recreational cannabis laws is associated with increased cannabis use disorder (CUD) and/or cannabis poisoning among adults is not evident. Objective: To examine state-level...
3.
Samet J, El-Bassel N, Winhusen T, Jackson R, Oga E, Chandler R, et al.
N Engl J Med . 2024 Jun; 391(11):989-1001. PMID: 38884347
Background: Evidence-based practices for reducing opioid-related overdose deaths include overdose education and naloxone distribution, the use of medications for the treatment of opioid use disorder, and prescription opioid safety. Data...
4.
Freeman P, Hammerslag L, Ahrens K, Sharbaugh M, Gordon A, Austin A, et al.
JAMA Health Forum . 2024 May; 5(5):e241077. PMID: 38758569
Importance: Controlled substances have regulatory requirements under the US Federal Controlled Substance Act that must be met before pharmacies can stock and dispense them. However, emerging evidence suggests there are...
5.
Hammerslag L, Mack A, Chandler R, Fanucchi L, Feaster D, Larochelle M, et al.
JAMA Netw Open . 2023 Oct; 6(10):e2336914. PMID: 37851446
Importance: Early COVID-19 mitigation strategies placed an additional burden on individuals seeking care for opioid use disorder (OUD). Telemedicine provided a way to initiate and maintain transmucosal buprenorphine treatment of...
6.
Rhudy C, Perry C, Hawk G, Flomenhoft D, Talbert J, Barrett T
Inflamm Bowel Dis . 2023 Jun; 30(3):410-422. PMID: 37280118
Background: Rural residence has been associated with a lower incidence of inflammatory bowel disease (IBD) but higher health care utilization and worse outcomes. Socioeconomic status is intrinsically tied to both...
7.
Hammerslag L, Campbell-Baier R, Otter C, Lopez-De Fede A, Smith J, Whittington L, et al.
Am J Obstet Gynecol MFM . 2023 Mar; 5(6):100937. PMID: 36933802
Background: Congenital syphilis can cause severe morbidity, including miscarriage and stillbirth, and rates are increasing rapidly within the United States. However, congenital syphilis can be prevented with early detection and...
8.
Bohler R, Freeman P, Villani J, Hunt T, Linas B, Walley A, et al.
Drug Alcohol Depend Rep . 2023 Jan; 6. PMID: 36643788
Background: Expanding access to naloxone is one of the most impactful interventions in decreasing opioid-related mortality. However, state distribution rates of naloxone are insufficient to meet community need. The current...
9.
Sohn M, Delcher C, Talbert J, Cheng Y, Xu Y, Jadhav E, et al.
Am J Prev Med . 2022 Dec; 64(4):483-491. PMID: 36496279
Introduction: Since 2017, a total of 10 states have mandated naloxone coprescribing intended to prevent fatal opioid overdoses. This study aims to assess the association between naloxone coprescribing/offering mandates and...
10.
Cheng Y, Freeman P, Slade E, Sohn M, Talbert J, Delcher C
J Rural Health . 2022 Nov; 39(2):347-354. PMID: 36333992
Purpose: The opioid crisis remains a major public health concern in the United States. Naloxone is used to reverse opioid overdoses. This study examined Medicaid expansion on naloxone prescriptions in...